1st Circ. Resurrects Investors' Fraud Claim Against Biogen
By Hailey Konnath · October 11, 2023, 11:34 PM EDT
The First Circuit on Wednesday revived one claim accusing Biogen Inc. of misleading investors about the effectiveness of its controversial Alzheimer's treatment aducanumab, though it held that the bulk of their...
To view the full article, register now.